Navigation Links
Pharmacyclics Announces Results of Registered Direct Offering
Date:6/17/2011

arbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations and beliefs regarding our future results or performance. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. Our actual results could differ materially from those projected in the forward-looking statements. Additionally, you should not consider past results to be an indication of our future performance. For a discussion of the risk factors and other factors that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

About Pharmacyclics

Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Third Quarter 2011
2. Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
3. Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011
4. Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
5. Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
6. Pharmacyclics, Inc. Rights Offering Oversubscribed
7. Pharmacyclics Announces Subscription Price for Rights Offering
8. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
9. Pharmacyclics Files Registration Statement for Rights Offering
10. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
11. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... for Molecular Medicine Finland (FIMM), University of Helsinki, ... "man and machine" decision support system for diagnosing ... in PLOS One scientific journal today, ... vision algorithms similar to those used in facial ... diagnostically most relevant areas. Tablet computers can be ...
(Date:8/21/2014)... August 21, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... therapy, is a means of replacing hormones ... the body. This type of therapy is ...
(Date:8/21/2014)... New Rochelle, N.Y. (PRWEB) August 21, 2014 ... it is the first private college in the Mid-Hudson ... The College will now begin accepting applications from qualified ... , “We are very pleased to have been ... to support Governor Cuomo’s transformative initiative to stimulate economic ...
(Date:8/21/2014)... , Aug. 21, 2014 ... Immune Pharmaceuticals Inc., a biotechnology company, on its ... Immune previously traded on OTCQX®, the best marketplace ... OTC Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... on the successful execution of its growth strategy ...
Breaking Biology Technology:A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... ,, NEW YORK , ... (SPOM),a leading developer of biosensor and microprocessor technologies for ... a unique bracelet,to measure the overall daily activity level ... are deemed to be overweight or obese. The bracelet,designed ...
... NUREMBERG , Germany , ... Imaging BV have joined forces to make the CAAS ... capability is the result of Ziehm Imaging,s strategic partnership ... ), a leading,developer of quantitative analysis software for cardiology ...
... ... effectively use this invaluable resource., , ... Seattle, WA (PRWEB) May 25, 2010 -- OpenHelix today ... is an integrated resource designed to provide access to current genetic testing and ...
Cached Biology Technology:SPO Medical Announces Innovative Wellness Bracelet 2SPO Medical Announces Innovative Wellness Bracelet 3SPO Medical Announces Innovative Wellness Bracelet 4SPO Medical Announces Innovative Wellness Bracelet 5Ziehm Imaging and Pie Medical Imaging Announce Cooperation 2Ziehm Imaging and Pie Medical Imaging Announce Cooperation 3Ziehm Imaging and Pie Medical Imaging Announce Cooperation 4Updated Online Tutorial for GeneTests 2
(Date:8/21/2014)... in smog-producing toxins in past decade, GTA still ... shows that while the Greater Toronto Area (GTA) ... contribute to smog, the city continues to violate ... which can cause or aggravate health problems such ... by a set of complex photochemical reactions involving ...
(Date:8/21/2014)... in near darkness use a previously unknown process for ... team led by a Penn State University scientist has ... aimed at improving plant growth, harvesting energy from the ... on Lake Erie and other lakes worldwide. A paper ... Science Express edition of the journal Science ...
(Date:8/21/2014)... Fla. , Aug. 21, 2014 /PRNewswire-iReach/ ... that it has agreed to a partnership ... Orlando,s fastest growing Certified Nursing ... Gabriel Health Institute  an exclusive member of ... result, Binary Biometrics will improve its service ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3
... the world’s largest and least studied freshwater turtles ... hopes that the threatened species can be saved ... World Wildlife Fund (WWF), the Cambodian Fisheries Administration, ... and released an 11-kilogram (24.2-pound) female Cantor’s giant ...
... have constructed the first global family tree of metabolic ... the evolutionary history of metabolism. , The study appears ... of the National Academy of Sciences. , Their ... in the past decade to plot the evolution of ...
... a mechanistic diagram describing the development of the Nematode ... been able to tease out what laboratory experiments have ... signaling pathways takes place in order to determine the ... is described in a paper appearing May 18, 2007 ...
Cached Biology News:Rare soft-shell turtle, nesting ground found in Cambodia 2Rare soft-shell turtle, nesting ground found in Cambodia 3Study of protein folds offers insight into metabolic evolution 2Study of protein folds offers insight into metabolic evolution 3Executable biology -- Computer science sheds light on animal development 2
... , Maintenance 112 days/each , ... Immunizations/Boost injections x5 /each , ... , Production bleed (25 ml blood =12 ml ... ml blood (~50 ml serum) x1 each , ...
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
chk 1 kinase...
muscle actin (HUC1-1)...
Biology Products: